Information Provided By: 
Fly News Breaks for March 22, 2019
ABT, EW
Mar 22, 2019 | 08:23 EDT
BMO Capital analyst Joanne Wuensch raised her price target on Edwards Lifesciences (EW) to $204 and kept her Outperform rating while removing the stock from her Top Picks list after its 25% year-to-date run-up. While there are some mid-year catalysts for the company such as the outcomes from the CMS NationalCoverage Decision proposal on March 27, clinical data from Pascal, and patent litigation with Abbott (ABT) regarding Pascal, the analyst contends that some consolidation in the stock price would not be surprising.
News For EW;ABT From the Last 2 Days
